Advertisement

Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer

  • Vahé Barsegian
  • Stefan P. Müller
  • Daniel Möckel
  • Peter A. Horn
  • Andreas Bockisch
  • Monika LindemannEmail author
Original Article

Abstract

Purpose

Therapy with the alpha-emitter radium-223 chloride (223Ra) is an innovative therapeutic option in patients with metastasized, castration-resistant prostate cancer. However, radiotherapy can lead to hematopoietic toxicity. The aim of this study was to determine if 223Ra therapy induces an impairment of cellular antimicrobial immune responses.

Methods

In 11 patients receiving 223Ra treatment, lymphocyte proliferation and the production of pro- and anti-inflammatory cytokines (interferon-γ and interleukin-10) were determined, using lymphocyte transformation testing and ELISpot, respectively. Lymphocyte function after stimulation with mitogens and microbial antigens was assessed prior to therapy and at day 1, 7 and 28 after therapy.

Results

Lymphocyte proliferation and the production of interferon-γ and interleukin-10 towards mitogens and antigens remained unchanged after therapy. Consistent with these in vitro data, we did not observe infectious complications after treatment.

Conclusions

The results argue against an impairment of lymphocyte function after 223Ra therapy. Thus, immune responses against pathogens should remain unaffected.

Keywords

Radium-223 therapy Antimicrobial immune response Lymphocyte proliferation ELISpot Cytokine 

Notes

Acknowledgments

The authors would like to thank Monika Huben and Martina Praast for their excellent technical assistance.

Authors’ contributions

M.L., V.B., S.P.M., P.A.H. and A.B. contributed to the conception and design of the study. V.B. and M.L. wrote the report. V.B. and D.M. recruited the patients and took blood samples. M.L. and V.B. performed the cellular in vitro assays. All authors read and approved the final manuscript.

Compliance with ethical standards

Funding

This study was performed without external funding.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.CrossRefGoogle Scholar
  2. 2.
    Miederer M, Thomas C, Beck J, Hampel C, Krieger C, Baque PE, et al. Haematopoietic toxicity of radium-223 in patients with high skeletal tumour burden. Nuklearmedizin. 2015;54:197–203.CrossRefGoogle Scholar
  3. 3.
    Humm JL, Sartor O, Parker C, Bruland OS, Macklis R. Radium-223 in the treatment of osteoblastic metastases: a critical clinical review. Int J Radiat Oncol Biol Phys. 2015;91:898–906.CrossRefGoogle Scholar
  4. 4.
    Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.CrossRefGoogle Scholar
  5. 5.
    Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res. 2013;5:1–14.CrossRefGoogle Scholar
  6. 6.
    Carrasquillo JA, Donoghue JAO, Pandit-Taskar N, Rathkopf DE, Aksnes A, Viner CL, et al. Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to bone. J Clin Oncol. 2010;28:Abstract 4680.Google Scholar
  7. 7.
    Barsegian V, Müller SP, Horn PA, Bockisch A, Lindemann M. Lymphocyte function following radioiodine therapy in patients with thyroid carcinoma. Nuklearmedizin. 2011;50:195–203.CrossRefGoogle Scholar
  8. 8.
    Barsegian V, Hueben C, Mueller SP, Poeppel TD, Horn PA, Bockisch A, et al. Impairment of lymphocyte function following yttrium-90 DOTATOC therapy. Cancer Immunol Immunother. 2015;64:755–64.CrossRefGoogle Scholar
  9. 9.
    Stevenson AF, Daculsi R, Monig H. Haematological studies on 90Sr-90Y-toxicity: II. Femoral CFU-s kinetics and mitogen response of spleen cells. Radiat Environ Biophys. 1982;20:275–87.CrossRefGoogle Scholar
  10. 10.
    Guedeney G, Grunwald D, Malarbet JL, Doloy MT. Time dependence of chromosomal aberrations induced in human and monkey lymphocytes by acute and fractionated exposure to 60Co. Radiat Res. 1988;116:254–62.CrossRefGoogle Scholar
  11. 11.
    Anderson RE, Lefkovits I. Effects of irradiation on the in vitro immune response. Exp Cell Biol. 1980;48:255–78.Google Scholar
  12. 12.
    Tiepolt C, Gruning T, Franke WG. Renaissance of 224 Ra for the treatment of ankylosing spondylitis: clinical experiences. Nucl Med Commun. 2002;23:61–6.CrossRefGoogle Scholar
  13. 13.
    Lindemann M, Witzke O, Winterhagen T, Ross B, Kreuzfelder E, Reinhardt W, et al. T-cell function after interleukin-2 therapy in HIV-infected patients is correlated with serum cortisol concentrations. AIDS. 2004;18:2001–7.CrossRefGoogle Scholar
  14. 14.
    Lindemann M, Virchow S, Ramann F, Barsegian V, Kreuzfelder E, Siffert W, et al. The G protein beta3 subunit 825T allele is a genetic marker for enhanced T cell response. FEBS Lett. 2001;495:82–6.CrossRefGoogle Scholar
  15. 15.
    EXINI Diagnostics. EXINI bone BSI. 2012. http://exini.com/software/exini-bone-bsi/. Accessed July 1 2016.
  16. 16.
    Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol. 2012;62:78–84.CrossRefGoogle Scholar
  17. 17.
    Erdi YE, Humm JL, Imbriaco M, Yeung H, Larson SM. Quantitative bone metastases analysis based on image segmentation. J Nucl Med. 1997;38:1401–6.Google Scholar
  18. 18.
    Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter Ra-223: Adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12:6250s-7s.Google Scholar
  19. 19.
    Ugurel S, Lindemann M, Schadendorf D, Grosse-Wilde H. Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation? Cancer Immunol Immunother. 2004;53:1051.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Institute of Nuclear MedicineHelios KlinikenSchwerinGermany
  2. 2.Department of Nuclear MedicineUniversity Hospital EssenEssenGermany
  3. 3.Institute for Transfusion MedicineUniversity Hospital EssenEssenGermany

Personalised recommendations